Asceneuron develops effective therapeutics for orphan tauopathies such as progressive supranuclear palsy (PSP) and Alzheimer’s disease. By focusing on areas of high unmet medical need, Asceneuron aspires to become a leading biotech company specialized in small molecule drug discovery for neurodegenerative diseases. Our first candidate molecule for PSP is aimed at preventing the formation of toxic tau aggregates by a groundbreaking new molecular mechanism and is currently progressed towards the clinic.

Orphan Tauopathies

Tauopathies are currently untreatable neurodegenerative diseases that rapidly progress towards debilitating conditions. The appearance of deposits of the microtubule-associated tau protein as e.g. neurofibrillary tangles in neurons of the brain is a common feature of tauopathies that is shared with Alzheimer’s disease. Neuronal tau deposits are known to be a major driver of neurodegeneration and mutations in the tau gene are causative of certain tauopathies.

Cognitive Improvement

Memory impairment and cognitive decline is major clinical symptom in a large number of neurological and neuropsychiatric diseases such as Alzheimer’s disease, Parkinson’s disease and Schizophrenia. Current pro-cognitive treatment options provide limited benefits supporting the urgent need for more efficacious and better tolerated medicines that address symptomatic relief as well as disease progression.